Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses

Nguyen, Long Chi; Yang, Dan; Nicolaescu, Vlad; Best, Thomas; Gula, Haley; Saxena, Divyasha; Gabbard, Jon D.; Chen, Shao-Nong; Ohtsuki, Takashi; Friesen, J. Brent; Drayman, Nir; Mohamed, Adil; Dann, Christopher; Silva, Diane; Robinson-Mailman, Lydia; Valdespino, Andrea; Stock, Letícia; Suárez, Eva Amanda del Pilar Gallego; Jones, Kohar; Azizi, Saara-Anne; DeMarco, Jennifer K; Severson, William; Anderson, Charles D.; Millis, Michael; Dickinson, Bryan C.; Tay, Savaş; Oakes, Scott A.; Pauli, Guido F.; Palmer, Kenneth E.; Chute, Christopher G; Meltzer, David O.; Randall, Glenn; Rosner, Marsha Rich

doi:10.1126/sciadv.abi6110

Cited by 103 publications

(82 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study presented an interesting finding in natural products, as cannabidiol (CBD) for the treatment of the COVID-19 disease ( 13 ). In their study, they found that CBD and its metabolite 7-OH-CBD can block SARS-CoV-2 replication.…”

Section: Cbd and The Proteins Encoded By Sars-cov-2mentioning

confidence: 99%

“…CBD acts after viral entry by reversing the transcription of host genes and their expression. CBD can increase the IRE1-alpha RNase endoplasmic reticulum stress response and the interferon pathways ( 13 ). The primary target for entry into host cells has been identified to be the multifunctional protein angiotensin-converting enzyme-related carboxypeptidase (ACE2) discovered simultaneously by Donoghue et al.…”

Section: Cbd and The Proteins Encoded By Sars-cov-2mentioning

confidence: 99%

“…This molecule can decrease the release of proinflammatory cytokines responsible for inflammation during SARS-CoV-2 infection ( 4 ). CBD can enhance the interferon pathway which leads to the activation of the host immune response to viral pathogens ( 13 ). The interferon pathway is a well-known signaling targeted as a possible treatment for COVID-19 ( 44 ).…”

Section: Cbd and The Cytokine Storm In Sars-cov-2 Infectionmentioning

confidence: 99%

“…Moreover, an in vitro investigation of a mixture of terpene with CBD use in human coronavirus E229i, as the combination of NT-VRL-1 (terpene-based formulation) with CBD, enhanced the antiviral effect ( 34 ). Furthermore, it was observed that CBD in combination with 7-OH-CBD can be used to lower SARS-CoV-2 infection occurring in patients ( 13 ) ( Table 1 ).…”

Section: Cbd and Antiviral Actions In Sars-cov-2 Infectionmentioning

confidence: 99%

See 3 more Smart Citations

Cannabidiol and SARS-CoV-2 Infection

Vallée

2022

Front. Immunol.

View full text Add to dashboard Cite

Cannabidiol (CBD) can prevent the inflammatory response of SARS-CoV-2 spike protein in Caco-2-cells. This action is coupled with the inhibition of IL-1beta, IL-6, IL-18, and TNF-alpha, responsible for the inflammatory process during SARS-CoV-2 infection. CBD can act on the different proteins encoded by SARS-CoV-2 and as an antiviral agent to prevent the viral infection. Furthermore, recent studies have shown the possible action of CBD as an antagonist of cytokine release syndromes. In the SARS-CoV-2 pathophysiology, the angiotensin-converting enzyme 2 (ACE2) seems to be the key cell receptor for SARS-CoV-2 infection. The WNT/β-catenin pathway and PPARγ interact in an opposite manner in many diseases, including SARS-CoV-2 infection. CBD exerts its activity through the interaction with PPARγ in SARS-CoV-2 infection. Thus, we can hypothesize that CBD may counteract the inflammatory process of SARS-CoV-2 by its interactions with both ACE2 and the interplay between the WNT/β-catenin pathway and PPARγ. Vaccines are the only way to prevent COVID-19, but it appears important to find therapeutic complements to treat patients already affected by SARS-CoV-2 infection. The possible role of CBD should be investigated by clinical trials to show its effectiveness.

show abstract

Section: Cbd and The Proteins Encoded By Sars-cov-2mentioning

confidence: 99%

Section: Cbd and The Proteins Encoded By Sars-cov-2mentioning

confidence: 99%

Section: Cbd and The Cytokine Storm In Sars-cov-2 Infectionmentioning

confidence: 99%

Section: Cbd and Antiviral Actions In Sars-cov-2 Infectionmentioning

confidence: 99%

See 2 more Smart Citations

Cannabidiol and SARS-CoV-2 Infection

Vallée

2022

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In this case, CBD inhibits SARS-CoV-2 replication in the early stages of the disease. This relationship is therefore indicated by Nguyen et al as a very effective potential measure to prevent infection in the early stages of infection; however, further testing and clinical trials are needed to clearly confirm the effects of cannabidiol on this virus [ 97 , 98 ].…”

Section: Characteristics Of Hemp Plantsmentioning

confidence: 99%

Hemp and Its Derivatives as a Universal Industrial Raw Material (with Particular Emphasis on the Polymer Industry)—A Review

Tutek

Masek

2022

Materials

View full text Add to dashboard Cite

This review article provides basic information about cannabis, its structure, and its impact on human development at the turn of the century. It also contains a brief description of the cultivation and application of these plants in the basic branches of the economy. This overview is also a comprehensive collection of information on the chemical composition of individual cannabis derivatives. It contains the characteristics of the chemical composition as well as the physicochemical and mechanical properties of hemp fibers, oil, extracts and wax, which is unique compared to other review articles. As one of the few articles, it approaches the topic in a holistic and evolutionary way, moving through the plant’s life cycle. Its important element is examples of the use of hemp derivatives in polymer composites based on thermoplastics, elastomers and duroplasts and the influence of these additives on their properties, which cannot be found in other review articles on this subject. It indicates possible directions for further technological development, with particular emphasis on the pro-ecological aspects of these plants. It indicates the gaps and possible research directions in basic knowledge on the use of hemp in elastomers.

show abstract

Cannabis, Tobacco Use, and COVID-19 Outcomes

Griffith,

Baker,

Heiden

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceIt is unclear whether cannabis use is associated with adverse health outcomes in patients with COVID-19 when accounting for known risk factors, including tobacco use.ObjectiveTo examine whether cannabis and tobacco use are associated with adverse health outcomes from COVID-19 in the context of other known risk factors.Design, Setting, and ParticipantsThis retrospective cohort study used electronic health record data from February 1, 2020, to January 31, 2022. This study included patients who were identified as having COVID-19 during at least 1 medical visit at a large academic medical center in the Midwest US.ExposuresCurrent cannabis use and tobacco smoking, as documented in the medical encounter.Main Outcomes and MeasuresHealth outcomes of hospitalization, intensive care unit (ICU) admission, and all-cause mortality following COVID-19 infection. The association between substance use (cannabis and tobacco) and these COVID-19 outcomes was assessed using multivariable modeling.ResultsA total of 72 501 patients with COVID-19 were included (mean [SD] age, 48.9 [19.3] years; 43 315 [59.7%] female; 9710 [13.4%] had current smoking; 17 654 [24.4%] had former smoking; and 7060 [9.7%] had current use of cannabis). Current tobacco smoking was significantly associated with increased risk of hospitalization (odds ratio [OR], 1.72; 95% CI, 1.62-1.82; P &lt; .001), ICU admission (OR, 1.22; 95% CI, 1.10-1.34; P &lt; .001), and all-cause mortality (OR, 1.37, 95% CI, 1.20-1.57; P &lt; .001) after adjusting for other factors. Cannabis use was significantly associated with increased risk of hospitalization (OR, 1.80; 95% CI, 1.68-1.93; P &lt; .001) and ICU admission (OR, 1.27; 95% CI, 1.14-1.41; P &lt; .001) but not with all-cause mortality (OR, 0.97; 95% CI, 0.82-1.14, P = .69) after adjusting for tobacco smoking, vaccination, comorbidity, diagnosis date, and demographic factors.Conclusions and RelevanceThe findings of this cohort study suggest that cannabis use may be an independent risk factor for COVID-19–related complications, even after considering cigarette smoking, vaccination status, comorbidities, and other risk factors.

show abstract

Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses

Cited by 103 publications

References 49 publications

Cannabidiol and SARS-CoV-2 Infection

Cannabidiol and SARS-CoV-2 Infection

Hemp and Its Derivatives as a Universal Industrial Raw Material (with Particular Emphasis on the Polymer Industry)—A Review

Cannabis, Tobacco Use, and COVID-19 Outcomes

Contact Info

Product

Resources

About